91 related articles for article (PubMed ID: 16304247)
1. What's in a day?
Milbrandt EB; Angus DC
Chest; 2005 Nov; 128(5):3091-3. PubMed ID: 16304247
[No Abstract] [Full Text] [Related]
2. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
5. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
[TBL] [Abstract][Full Text] [Related]
6. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
7. [Antibiotic therapy of severe community-acquired pneumonia].
Molchanova OV; Suleĭmanov SSh; Ostrovskiĭ AB
Antibiot Khimioter; 2009; 54(3-4):29-31. PubMed ID: 19711847
[TBL] [Abstract][Full Text] [Related]
8. [The clinical and economic aspects of treating community-acquired pneumonias].
Tiurin VP; Dmitriev IuK; Duganov VK; Bogdanov MB
Voen Med Zh; 2000 Apr; 321(4):28-31. PubMed ID: 10860468
[No Abstract] [Full Text] [Related]
9. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
Rahav G; Fidel J; Gibor Y; Shapiro M
Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
[TBL] [Abstract][Full Text] [Related]
10. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
11. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
[TBL] [Abstract][Full Text] [Related]
12. [Azithromycin (sumamed)--basic properties and therapy of community-acquired pneumonia].
Budanov SV
Antibiot Khimioter; 2000; 45(10):28-37. PubMed ID: 11212397
[No Abstract] [Full Text] [Related]
13. [Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?].
Torralba MÁ; Matía M; Gómez del Valle C; Pérez-Calvo JI
Med Clin (Barc); 2010 Oct; 135(12):576-7. PubMed ID: 19819496
[No Abstract] [Full Text] [Related]
14. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
[No Abstract] [Full Text] [Related]
15. [Uncomplicated community-acquired pneumonia. Under control in 3 treatment days].
MMW Fortschr Med; 2003 Jan; 145(3-4):58. PubMed ID: 12619240
[No Abstract] [Full Text] [Related]
16. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Mokabberi R; Haftbaradaran A; Ravakhah K
J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
[TBL] [Abstract][Full Text] [Related]
17. Community-acquired pneumonia: treatment at home or in the hospital?
Aujesky D; Fine MJ
Am J Med; 2008 Dec; 121(12):1038-40. PubMed ID: 19028194
[No Abstract] [Full Text] [Related]
18. [Clinical experience of levofloxacin in community acquired pneumonia].
Arancibia F; Maldonado A; Torres A
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():14-8. PubMed ID: 10563105
[No Abstract] [Full Text] [Related]
19. Community-acquired pneumonia.
Niederman MS
Isr Med Assoc J; 2003 Feb; 5(2):133-8. PubMed ID: 12674669
[No Abstract] [Full Text] [Related]
20. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Halpern MT; Cifaldi MA
Clin Infect Dis; 2004 Jul; 39(1):144-5; author reply 145-6. PubMed ID: 15206068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
